Home Credit Ratings and Research Residential Mortgage-Backed Securities S&P Global Ratings’ Credit Research Bristol-Myers Squibb Co.

BULLETIN: Bristol-Myers Squibb Co. Renegotiates Codevelopment Agreement on Erbitux

Published Mar 06, 2002

Price US$ 150.00 | Buy this Report Now

About This Report

Abstract:

Bristol-Myers Squibb Co. (AAA/Negative/A-1+) has renegotiated its codevelopment partnership agreement for ImClone's cancer treatment, Erbitux, now that the FDA is willing to review Erbitux for approval, if additional data is submitted. The development, although positive in that the development of Erbitux appears to be back on track, does not have an impact on Standard&Poor's current ratings or outlook. The outlook is more dependent on the actual launch and successful commercialization of Bristol-Myers near-term drug prospects, including Erbitux.

Report Type:

News

Ticker

BMY

Issuer

Bristol-Myers Squibb Co.

GICS

Pharmaceuticals (35202010)

Sector

Global Issuers , Structured Finance

Country

United States

Region

United States

Format:

HTML

BULLETIN: Bristol-Myers Squibb Co. Reports Disappointing Results for New Drug – 2002/03/21 – US$ 150.00

Bristol-Myers Squibb Co. Corporate Credit Rating Placed on Watch Negative – 2002/04/04 – US$ 150.00

Summary: Bristol-Myers Squibb Co. – 2002/04/04 – US$ 225.00

Bristol-Myers Squibb Long-Term Ratings Remain on Watch Negative In View of SEC Investigation – 2002/07/12 – US$ 150.00

Research Update: Bristol-Myers Squibb Co. – 2002/07/12 – US$ 225.00

Summary: Bristol-Myers Squibb Co. – 2002/03/01 – US$ 225.00

BULLETIN: Bristol-Myers Squibb Co. Seeks Changes to Drug Partnership With ImClone – 2002/02/07 – US$ 150.00

BULLETIN: Bristol-Myers Squibb Co. and ImClone Systems' Cancer Drug Approval Delayed – 2002/01/02 – US$ 150.00

BULLETIN: Bristol-Myers Squibb Co. Warns of Lower Earnings in 2002 due to Generic Competition – 2001/12/14 – US$ 150.00

BULLETIN:Bristol-Myers Squibb Co. to Cut Another 1,000 Jobs – 2001/11/19 – US$ 150.00

More from S&P Global Ratings’ Credit Research

S&P Global Ratings’ Credit Research—S&P Global Ratings’ credit research provides analysis on issuers and debt obligations of corporations, states and municipalities, financial institutions, insurance companies and sovereign governments. S&P Global Ratings also offers insight into the credit risk of structured finance deals, providing an independent view of credit risk associated with a growing array of debt-securitized instruments.

About the Author

Cite this Report


MLA:	S&P Global Ratings’ Credit Research. "BULLETIN: Bristol-Myers Squibb Co. Renegotiates Codevelopment Agreement on Erbitux" Mar 06, 2002. Alacra Store. May 25, 2025. <http://www.alacrastore.com/s-and-p-credit-research/BULLETIN-Bristol-Myers-Squibb-Co-Renegotiates-Codevelopment-Agreement-on-Erbitux-233790>

APA:	S&P Global Ratings’ Credit Research. (). BULLETIN: Bristol-Myers Squibb Co. Renegotiates Codevelopment Agreement on Erbitux Mar 06, 2002. New York, NY: Alacra Store. Retrieved May 25, 2025 from <http://www.alacrastore.com/s-and-p-credit-research/BULLETIN-Bristol-Myers-Squibb-Co-Renegotiates-Codevelopment-Agreement-on-Erbitux-233790>

US$ 150.00

$ £ €

Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

Example Report

Click to View Sample Report

More Research

Search all our Residential Mortgage-Backed Securities from one place.